Québec supports $38m Galderma investment
pharmafile | February 18, 2010 | News story | Manufacturing and Production | Canada, Galderma, Quebec, biopharmaceutical
The regional government in Québec in Canada is to contribute 10% of the costs of a new investment in manufacturing by Galderma.
Québec will contribute 3.8-million Canadian dollars in the form of a ‘non-refundable financial contribution’ towards Galderma’s plans to modernise and expand its drug manufacturing site in Baie-d’Urfé.
A specialist in dermatology, Galderma operates three research and development centres (in France, the United States and Japan) as well as three manufacturing facilities in France, Brazil and Canada.
Estimated at a value of more than $38 million, the capital investment project aims to increase the Baie-d’Urfé plant’s competitive ability and export potential and position it as an international centre of excellence for manufacturing and distributing the Cetaphil product line. In addition, the project will enable the company to consolidate over 240 positions and create some 30 new specialised jobs.
Clément Gignac, Minister of Economic Development, Innovation and Export Trade for Québec said the deal was beneficial for the province.
“Representing over 145 companies and nearly 20,900 direct jobs, the biopharmaceutical industry is a rapidly emerging sector that’s playing a major role in developing and diversifying our economy,” says Gignac.
“We’re supporting the expansion of Galderma’s Baie-d’Urfé plant because it’ll help boost Québec’s international competitiveness in the life sciences industry. This dynamic force allows Québec to maintain its leadership in the Canadian biopharmaceutical industry.”
The financial incentive is part of Québec’s new biopharmaceutical strategy, which the government launched last autumn. The strategy sets out commitments and measures to support the industry’s growth and performance. It aims to preserve a favourable, dynamic and competitive business environment for all industry players.
“With this initiative, our government is positioning Québec as the location of choice for new biopharmaceutical investment projects,” says Geoffrey Kelley, a member of Québec’s provincial parliament. “This is also excellent news for the region’s specialised workers, who make up a stable, highly sought-after and competitive labour pool.”
“The government’s support was a decisive factor in Galderma’s decision to locate its centre of excellence in Québec,” says Michel Sauvageau, manager of the Baie-d’Urfé plant. “In response to the progress of emerging countries in biopharmaceuticals, this investment in our manufacturing facility will increase its capacity and make it truly state-of-the-art.”
Related Content
Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin
Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, …
ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models
Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced …
Biopharmaceutical company EQRx set to be acquired by Revolution Medicines
On 1 August 2023, Revolution Medicines signed an official agreement confirming the acquisition of the …
